Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GNI Group ( (JP:2160) ) has issued an update.
GNI Group Ltd. announced that its subsidiary, Gyre Therapeutics, has acquired additional shares in Gyre Pharmaceuticals, increasing its equity interest to 69.72%. This strategic move aims to minimize profit outflows to minority shareholders and enhance the Group’s corporate value, particularly as Gyre Pharmaceuticals is set to handle the entire value chain for a new liver fibrosis drug candidate. The acquisition is expected to positively impact the Group’s financial results, although the exact effect is still under review.
The most recent analyst rating on (JP:2160) stock is a Buy with a Yen3700.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.
More about GNI Group
GNI Group Ltd. operates in the pharmaceutical industry, focusing on developing and commercializing innovative drugs. Its primary products include treatments for liver fibrosis and other chronic conditions, with a market focus on expanding its equity interests and maximizing corporate value.
Average Trading Volume: 2,181,193
Technical Sentiment Signal: Buy
Current Market Cap: Yen147.7B
Find detailed analytics on 2160 stock on TipRanks’ Stock Analysis page.